Paired Ends: Kevin Hrusovsky

Premium

SynapDx has appointed Kevin Hrusovsky to the firm's board of directors. He most recently served as president of life sciences and technology at PerkinElmer. Hrusovsky had been CEO of Caliper Life Sciences from 2003 to 2011, when the firm was purchased by PerkinElmer for more than $600 million. He left PerkinElmer earlier this year but agreed to serve as a consultant for up to one year. He also serves on the board of directors of 908 Devices.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.